Brainstorm Cell Therapeutics shares are trading lower after the company announced the FDA Advisory Committee voted that NurOwn did not demonstrate substantial evidence of effectiveness for treatment of mild to moderate ALS.
Portfolio Pulse from Benzinga Newsdesk
Brainstorm Cell Therapeutics announced that the FDA Advisory Committee voted that its product, NurOwn, did not demonstrate substantial evidence of effectiveness for treatment of mild to moderate ALS. This has led to a decrease in the company's share price.
September 28, 2023 | 1:02 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Brainstorm Cell Therapeutics' shares are trading lower after the FDA Advisory Committee voted that its product, NurOwn, did not demonstrate substantial evidence of effectiveness for treatment of ALS.
The FDA Advisory Committee's vote against the effectiveness of Brainstorm Cell Therapeutics' product, NurOwn, is a significant setback for the company. This negative regulatory decision directly impacts the company's potential revenue from this product, leading to a decrease in its share price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100